Genentech buys Regor’s CDK inhibitors in $850m deal - Yahoo …
WEB7 hours ago · Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer cyclin-dependent kinase (CDK) inhibitors in an $850m deal. The deal, anticipated...
Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Regor Pharmaceuticals (USA) ("Regor") has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK...
Genentech buys Regor's next-gen CDK inhibitors for $850M
WEB1 day ago · Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash...
Genentech inks $850M upfront deal for Regor's CDK inhibitors
WEB1 day ago · Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in...
Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for …
WEB1 day ago · Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment of $850 million.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
WEB9 hours ago · RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Genentech To Acquire Portfolio Of Next-generation CDK …
WEB1 day ago · (RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK...
Roche turns to a startup in search for new breast cancer drugs
WEB2 days ago · Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by China-based biotechnology startup Regor Therapeutics. The deal hands Roche two medicines that Regor, in a statement, described as “next-generation” versions of the CDK inhibitors widely used to …
Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB2 days ago · Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones.
Roche Doubles Down on Breast Cancer With $850M for Regor’s …
WEB1 day ago · A portfolio of CDK inhibitors developed by Regor Pharmaceuticals has found a home at Roche, which announced Monday it would buy the investigational cancer drugs for $850 million upfront.
- Some results have been removed